240 related articles for article (PubMed ID: 16185093)
1. Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Neuhaus O; Stüve O; Zamvil SS; Hartung HP
CNS Drugs; 2005; 19(10):833-41. PubMed ID: 16185093
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
Neuhaus O; Hartung HP
Expert Rev Neurother; 2007 May; 7(5):547-56. PubMed ID: 17492904
[TBL] [Abstract][Full Text] [Related]
3. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
Neuhaus O; Stüve O; Archelos JJ; Hartung HP
J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
[TBL] [Abstract][Full Text] [Related]
4. Are statins a treatment option for multiple sclerosis?
Neuhaus O; Stüve O; Zamvil SS; Hartung HP
Lancet Neurol; 2004 Jun; 3(6):369-71. PubMed ID: 15157852
[TBL] [Abstract][Full Text] [Related]
5. Statin treatment in multiple sclerosis: a systematic review and meta-analysis.
Pihl-Jensen G; Tsakiri A; Frederiksen JL
CNS Drugs; 2015 Apr; 29(4):277-91. PubMed ID: 25795002
[TBL] [Abstract][Full Text] [Related]
6. [Effects of atorvastatin in multiple sclerosis].
Koh CS
Nihon Rinsho; 2003 Aug; 61(8):1455-60. PubMed ID: 12962038
[TBL] [Abstract][Full Text] [Related]
7. Role of statins in the treatment of multiple sclerosis.
Ciurleo R; Bramanti P; Marino S
Pharmacol Res; 2014 Sep; 87():133-43. PubMed ID: 24657241
[TBL] [Abstract][Full Text] [Related]
8. The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis.
Stefanou MI; Palaiodimou L; Katsanos AH; Milionis H; Kosmidou M; Lambadiari V; Halvatsiotis P; Ferentinos P; Andreadou E; Marinos G; Theodorou A; Tzartos JS; Voumvourakis K; Tsivgoulis G; Giannopoulos S
Mult Scler Relat Disord; 2022 Feb; 58():103395. PubMed ID: 35216778
[TBL] [Abstract][Full Text] [Related]
9. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS
Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218
[TBL] [Abstract][Full Text] [Related]
10. Comparative tolerability of the HMG-CoA reductase inhibitors.
Farmer JA; Torre-Amione G
Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
13. The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?
Sellner J; Weber MS; Vollmar P; Mattle HP; Hemmer B; Stüve O
CNS Neurosci Ther; 2010 Dec; 16(6):362-73. PubMed ID: 20626428
[TBL] [Abstract][Full Text] [Related]
14. [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].
Neuhaus O; Wiendl H; Kieseier BC; Archelos JJ; Hartung HP
Nervenarzt; 2003 Aug; 74(8):704-7. PubMed ID: 12904873
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
18. HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?
Schlienger RG; Meier CR
Drugs Aging; 2003; 20(5):321-36. PubMed ID: 12696993
[TBL] [Abstract][Full Text] [Related]
19. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
Davidson MH
Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
[TBL] [Abstract][Full Text] [Related]
20. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
